Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

Christina Sølund, Sofie Hallager, Martin S. Pedersen, Ulrik Fahnøe, Anja Ernst, Henrik B. Krarup, Birgit T. Røge, Peer B. Christensen, Alex L. Laursen, Jan Gerstoft, Erika Bélard, Lone G. Madsen, Kristian Schønning, Anders G. Pedersen, Jens Bukh, Nina Weis, The DANHEP Group

19 Citationer (Scopus)

Abstract

AbstractObjectives: We describe factors associated with and barriers to initiation of Direct Acting Antiviral (DAA) treatment in patients with chronic hepatitis C, who fulfill national fibrosis treatment guidelines in Denmark.Materials and Methods: In this nationwide cohort study, we included patients with chronic hepatitis C from The Danish Database for Hepatitis B and C (DANHEP) who fulfilled fibrosis treatment criteria. Factors associated with treatment initiation and treatment failure were determined by logistic regression analyses. Medical records were reviewed from patients who fulfilled fibrosis treatment criteria, but did not initiate DAA treatment to determine the cause.Results: In 344 (49%) of 700 patients, who fulfilled treatment criteria, factors associated with DAA treatment initiation were transmission by other routes than injecting drug use odds ratio (OR) 2.13 (CI: 1.38–3.28), previous treatment failure OR 2.58 (CI: 1.84–3.61) and ALT above upper limit of normal OR 1.60 (CI: 1.18–2.17). Th...
OriginalsprogEngelsk
TidsskriftScandinavian Journal of Gastroenterology
Vol/bind53
Udgave nummer7
Sider (fra-til)849-856
ISSN0036-5521
DOI
StatusUdgivet - 1 maj 2018

Emneord

  • DAA,Direct Acting Antivirals,HCV,barriers to treatment,factors associated with treatment,hepatitis C virus,liver cancer,liver disease,treatment initiation

Citationsformater